Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant human thrombopoietin clinical development.

D V Jones1, M Ashby, S Vadhan-Raj

  • 1Genentech, Inc., South San Francisco, California, USA.

Stem Cells (Dayton, Ohio)
|September 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

3D TOF-PET image reconstruction using total variation regularization.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2020
Same author

Performance assessment of the 2 γpositronium imaging with the total-body PET scanners.

EJNMMI physics·2020
Same author

Estimating relationship between the time over threshold and energy loss by photons in plastic scintillators used in the J-PET scanner.

EJNMMI physics·2020
Same author

Evaluation of a surgical training programme for clinical officers in Malawi.

The British journal of surgery·2019
Same author

'I think we are going to leave these cases'. Obstacles to surgery in rural Malawi: a qualitative study of provider perspectives.

Tropical medicine & international health : TM & IH·2018
Same author

Reticulocyte and erythrocyte hypochromia markers in detection of iron deficiency in adolescent female athletes.

Biology of sport·2017
Same journal

Correction to: Mitochondrial Transfer from Mesenchymal Stem Cells to Macrophages Restricts Inflammation and Alleviates Kidney Injury in Diabetic Nephropathy Mice via PGC-1α Activation.

Stem cells (Dayton, Ohio)·2026
Same journal

Correction to: Critical role of the potential O-linked glycosylation sites of CXCR4 in cell migration and bone marrow homing of hematopoietic stem progenitor cells.

Stem cells (Dayton, Ohio)·2026
Same journal

Brent A. Reynolds, pioneer of adult neural stem cell biology.

Stem cells (Dayton, Ohio)·2026
Same journal

CircVapa promotes the abnormal differentiation of small intestinal epithelial stem cells in diabetic state.

Stem cells (Dayton, Ohio)·2026
Same journal

Transforming Growth Factor beta-2 (TGFβ2) Drives Trabecular Meshwork Progenitor Cell Differentiation Through SMAD2/3 Signalling.

Stem cells (Dayton, Ohio)·2026
Same journal

Circular RNA circEGFR overexpression attenuates chemosensitivity and enhances cancer stemness via targeting IGF2BP2/SOX2 in breast cancer cells.

Stem cells (Dayton, Ohio)·2026
See all related articles

Recombinant human thrombopoietin (rHuTPO) shows promise in managing chemotherapy-induced thrombocytopenia. This therapy may reduce bleeding risks and allow for consistent anticancer treatment delivery.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Anticancer therapies frequently cause thrombocytopenia, increasing bleeding risk and necessitating dose reductions.
  • Current treatment involves platelet transfusions, which carry risks of alloimmunization and infection.
  • Effective interventions for thrombocytopenia are crucial for maintaining optimal cancer treatment intensity.

Purpose of the Study:

  • To evaluate the safety and efficacy of recombinant human thrombopoietin (rHuTPO) in patients undergoing chemotherapy.
  • To assess rHuTPO's potential to mitigate chemotherapy-induced thrombocytopenia and its associated complications.

Main Methods:

  • Phase 1 clinical trials investigating rHuTPO in patients receiving myelosuppressive or myeloablative therapy.
  • Specific trials include rHuTPO in women with gynecologic malignancies and for progenitor cell mobilization in breast cancer patients.

Related Experiment Videos

Main Results:

  • Preliminary data from ongoing phase 1 trials will be presented.
  • The data will illustrate the safety and activity of rHuTPO in relevant patient populations.

Conclusions:

  • rHuTPO is a potential therapeutic agent for managing chemotherapy-induced thrombocytopenia.
  • Further studies are warranted to establish rHuTPO's role in supportive cancer care.